Due to its inability to penetrate the skin's intact structures, cells, and chemical defenses as well as the absence of other virulence factors including coagulase, adhesion proteins, and toxins found in Staphylococcus epidermidis rarely causes disease.
<h3>Staphylococcus epidermidis: What is it? </h3>
Staphylococcus epidermidis is one of more than 40 species of the Staphylococcus genus. It is a characteristic component of human flora and is also present in marine sponges. It is most frequently detected in skin flora and less frequently in mucosal flora. It is an anaerobic facultative bacteria.
Despite the fact that S. epidermidis is typically not harmful, people with weakened immune systems are more likely to get infections. These infections are typically acquired in hospitals. S. epidermidis is known to build biofilms that grow on catheters and other surgical implants, which is why it is particularly dangerous for patients who have them. S. epidermidis is a frequent contaminant of specimens sent to the diagnostic laboratory since it is a typical component of skin flora. Some S. epidermidis strains thrive in salty environments and are frequently found there.
To know more about staphylococcus epidermidis visit:
brainly.com/question/28045900
#SPJ4
Explanation:
Yeah.... I'm... Let's be friends
Answer:
Not enough T^T
Explanation:
Stress. Highschool is hard.
Why do you ask?
Answer:
true
Explanation:
The use of the dapagliflozin SGLT2 inhibitor is beneficial to reduce hospitalizations for heart failure
The cardiovascular benefits of the drug for diabetes dapagliflozin extend over a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the pumping capacity of the heart that indicates poor cardiac functioning,
The findings are derived from the 'DECLARE-TIMI 58' trial, which already showed in 2018 that dapagliflozin, part of a class of medications known as SGLT2 inhibitors, reduces the risk of cardiovascular death and hospitalizations for heart failure, regardless of ejection fraction or whether or not they had heart failure at the start of the study. However, the drug significantly decreased death rates from cardiovascular causes and death from all causes only among those who had a lower ejection fraction.
The use of the dapagliflozin SGLT2 inhibitor is beneficial to reduce hospitalizations for heart failure in patients with a wide range of left ventricular ejection fraction, but patients with reduced ejection fraction can obtain an even greater benefit.